levetiracetam
levetiracetam is listed in the FDA National Drug Code directory with 50 NDC codes, marketed under brand names including Spritam, Keppra XR, LEVETIRACETAM. Available dosage forms: tablet, for suspension, tablet, film coated, extended release, injection, injection, solution, concentrate, tablet, film coated.
Drug Details
- Generic Name
- levetiracetam
- Brand Names
- Spritam, Keppra XR, LEVETIRACETAM, Levetiracetam Extended-Release, Levetiracetam, levetiracetam, ELEPSIA XR 1500 MG, Keppra, ELEPSIA XR 1000 MG
- Application Number
- NDA207958
- Sponsor
- Aprecia Pharmaceuticals, LLC
- NDC Codes
- 50
- Dosage Forms
- TABLET, FOR SUSPENSION, TABLET, FILM COATED, EXTENDED RELEASE, INJECTION, INJECTION, SOLUTION, CONCENTRATE, TABLET, FILM COATED, INJECTION, SOLUTION, SOLUTION, TABLET, EXTENDED RELEASE, POWDER
- Routes
- ORAL, INTRAVENOUS
- Active Ingredients
- LEVETIRACETAM
Indications and Usage
1 INDICATIONS AND USAGE Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.